GlassScriptPhysician profile
Zachary Robert Windrow
NPI 1235161811
$2,050.83
in general payments reported to CMS, 2019-2025
22 companies · $373 in 2025
The $373 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.11 · 2020: $39.58 · 2021: $232 · 2022: $322 · 2023: $442 · 2024: $584 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,319 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,318.61 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $765.00 | 2021-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $231.08 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $225.72 | 2019-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Novo Nordisk INC | $149.71 | 2021-2024 | |
| Glaxosmithkline, LLC. | $124.25 | 2020-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $79.99 | 2024 | |
| Supernus Pharmaceuticals, INC. | $64.60 | 2022-2023 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $56.42 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $49.47 | 2021 | |
| Pfizer INC. | $47.21 | 2019-2025 | |
| Biogen, INC. | $39.33 | 2021-2022 | |
| Lundbeck LLC | $30.85 | 2024 | Rexulti |
| Dexcom, INC. | $26.56 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $22.29 | 2025 | The Cologuard Plus Collection Kit |
| Inspire Medical Systems, INC. | $21.22 | 2025 | Inspire |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $20.33 | 2019 | |
| Averitas Pharma INC. | $18.64 | 2024 | Qutenza |
| Amgen INC. | $17.89 | 2024 | Otezla, Repatha |
| Corium, LLC | $17.57 | 2022 | |
| Lilly USA, LLC | $15.42 | 2024 | Mounjaro |
| Currax Pharmaceuticals LLC | $14.51 | 2025 | Contrave |
| Genentech USA, INC. | $12.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Windrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.